Overview

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
Phase:
Phase 2
Details
Lead Sponsor:
Oregon Health and Science University